Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04519151 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 8, 2023 (before its estimated November 2023 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 7 to 8v4
  2. Primary completion date: Nov 2022 to Nov 2023
    • Secondary endpoints: 8 to 7
    • Study description expanded, about 484 words
    • Study title shortened, about 16 words
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2020 to Apr 12, 2021
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.
Trial Details
NCT Number NCT04519151
Lead Sponsor Sheba Medical Center
Conditions
(from sponsor)		 Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Neoplasm of Stomach, Ovarian Diseases, Genital Neoplasms, Female, Ovarian Epithelial Tumor, Urogenital Neoplasms, Neoplasms, Glandular and Epithelial
Related terms Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov